KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Non-Current Debt (2016 - 2023)

Exact Sciences (EXAS) has disclosed Non-Current Debt for 14 consecutive years, with $50.0 million as the latest value for Q1 2023.

  • Quarterly Non-Current Debt changed N/A to $50.0 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Mar 2023, changed N/A year-over-year, with the annual reading at $50.0 million for FY2022, N/A changed from the prior year.
  • Non-Current Debt for Q1 2023 was $50.0 million at Exact Sciences, roughly flat from $50.0 million in the prior quarter.
  • The five-year high for Non-Current Debt was $50.0 million in Q2 2022, with the low at $21.4 million in Q3 2021.
  • Average Non-Current Debt over 5 years is $31.3 million, with a median of $24.0 million recorded in 2019.
  • The sharpest move saw Non-Current Debt surged 2682.35% in 2019, then dropped 7.03% in 2020.
  • Over 5 years, Non-Current Debt stood at $24.0 million in 2019, then fell by 7.03% to $22.3 million in 2020, then decreased by 4.05% to $21.4 million in 2021, then surged by 133.23% to $50.0 million in 2022, then changed by 0.0% to $50.0 million in 2023.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $50.0 million, $50.0 million, and $50.0 million for Q1 2023, Q4 2022, and Q3 2022 respectively.